Life Science Investing Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Life Science Investing FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
Nextech3D.ai Announces CEO Evan Gappelberg Acquires 550,000 Shares of Company Stock In Open Market Buys